Navigation Links
Neurocrine Biosciences Reports Third Quarter 2012 Results
Date:10/31/2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and nine months ended September 30, 2012. For the third quarter of 2012, the Company reported a net loss of $3.1 million, or $0.05 loss per share, compared to net income of $31.4 million, or income of $0.56 per fully diluted share outstanding, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $4.5 million, or $0.07 loss per share, compared to net income of $36.2 million, or income of $0.64 per fully diluted share outstanding, for the first nine months of last year. During the third quarter of 2011, the Company recognized $30.0 million in milestone revenue under its collaboration agreement with Abbott.

The Company's balance sheet at September 30, 2012 reflected cash, cash equivalents, investments and receivables under collaboration agreements of $185.5 million. 

"Neurocrine continued to advance its development pipeline with our VMAT2 inhibitor entering Phase IIb clinical trials this past quarter," said Christopher O'Brien, Chief Medical Officer of Neurocrine Biosciences. "The KINECT study, along with the pending second Phase IIb study of NBI-98854 in tardive dyskinesia patients as well as information from the elagolix program will provide significant data flow over the coming quarters."

"Significant progress has also been made with elagolix," said Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences. "The Phase III study for elagolix in endometriosis is enrolling as planned, and the Phase II clinical trial in uterine fibroids is anticipated to complete in the first half of next year."

Revenues for the third quarter of 2012 were $9.4 million, compared to $41.6 million for the same period in 2011. Revenues for the nine months ended September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
7. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
9. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Francisco, CA (PRWEB) May 21, 2015 ... sequencing, has announced a partnership with PicnicHealth, a ... for patients. Participants diagnosed with Inflammatory Bowel Disease ... well as a complementary uBiome research kit. Both ... 2014. , For more information ...
(Date:5/21/2015)... May 21, 2015 Patent Offering, The ... for diagnostic or therapeutic imaging within a body lumen ... an endoscope having a low cost, single-use disposable illumination ... date was October 18, 2013 and the patent approval ... enables the physician to customize the lighting and magnification ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 Research and ... addition of the "Top Technologies in HW_Technical Insights" ... division of this report evaluated technology trends in the ... trends that are likely to have an impact in ... depth analysis of the top 10 health and wellness ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2
... , , ROCKAWAY, N.J., Dec. ... An Evidence-Based Approach , published by the ... for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy ... used in the treatment of various types of cancer since ...
... , WALTHAM, Mass., Dec. 14 Decision ... pharmaceutical and healthcare issues, finds that, owing to the launches of ... than sevenfold from $790 million in 2008 to $6.1 billion in ... Kingdom and Japan. , The new Pharmacor report entitled Atrial ...
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
Cached Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... Applying a small mechanical force to embryonic stem ... into a specific direction of differentiation, researchers at the ... include therapeutic cloning and regenerative medicine. "Our results suggest ... inducing strong biological responses in embryonic stem cells, and ...
... A 21-year Michigan State University experiment that distills the ... natural selection at work, but could lead to ... Darwin,s seminal Origin of Species first laid out the ... professor Richard Lenski and colleagues document the process in ...
... statewide group of structural biologists with similar interests in ... on the University of Oklahoma,s Norman campus with the ... sophisticated robotics equipment. The idea for the ... facilitated a meeting among structural biologists from the OU ...
Cached Biology News:Small mechanical forces have big impact on embryonic stem cells 2Time in a bottle: Scientists watch evolution unfold 2Time in a bottle: Scientists watch evolution unfold 3